Matinas Biopharma

Dyslipidemia treatments

MAT2501 Clin1 non-tuberculous mycobacterium infections (ODD)

Matinas Biopharma is improving the delivery method for nucleic acid therapeutics. Using their lipid nano-crystal (LNC) platform, Matinas is developing safe, intracellular, orally-administered delivery of a broad range of drug therapies, including small molecules, nucleic acid polymers, proteins, vaccines and gene editing technologies. LNCs are formulated as natural highly efficient spiral crystal, or “cochleate”, which encapsulates and protects drugs from harsh environments and releases them following fusion with the cell membrane. Matinas’ lead candidate, MAT2203, is an encochleated form of amphotericin B, an antifungal drug which is being tested for the treatment of invasive candidiasis and aspergillosis.